Ok. I just wanted to gauge the sentiment about the likelihood for any deals. Someone might be interested in buying them for the technology rights. It would be a very cheap M&A. They only have 33M shares, for anywhere in between $33M - $66M ( $1 - $2 ), they could get access to 3 drugs in large markets. Depends on how valuable these drugs really are.
Their seems to be some interest in tecarfarin in the cardiology community for it. Obviously their first major study didn't show superiority, but at least it wasn't inferior and lacked many side effects.
They also have other products in their pipeline worth discussing.
1- Budiodarone is an oral anti-arrhythmic agent in Phase 2b clinical development for the treatment of patients with atrial fibrillation. This has fairly good Phase 2b results and seems fairly marketable to a larger pharma
2- ATI-7505 also seems to have some value.
I'm still long ARYX and I established my entire position just after the Phase 3 tecarfarin debacle at just above $2/share. Things looked good for me for awhile as I believe the stock got above $3 briefly for awhile. Sadly, I didn't sell any shares as I thought a nice partnership for budiodarone was a strong likelihood given what appeared to me to be strong Phase 2b PoC results. However, that obviously never materialized for reasons none of us may ever know. I still think budiodarone appears to be a nice drug and it addresses a large market opportunity, but ARYX has absolutely no leverage IMO to pull off any kind of nice deal for the drug given that they are about to run out of cash. Also, the fact that the parties who were originally talking to ARYX about licensing budiodarone all walked away from the table is a pretty bad sign. Did they see something with the drug they didn't like or was ARYX just asking too much? Who knows?
Although ARYX is one of my worst biotech investments ever percentagewise and it's tempting to dollar-cost average at what appears to be really cheap levels given the market cap and the pipeline, it's just too risky for me to throw good money after bad with the company on the verge of bankruptcy. All told, I'm hoping they get bought out for much higher and I recoup some of my losses though I expect to ultimately exit with some sort of loss from the stock.
Market Data 
Markets 
AI
